Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Takeda Pharmaceutical Company Ltd (武田薬品工業株式会社 Takeda Yakuhin Kōgyō Kabushiki-gaisha) is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following merger with Shire). The company has over 30,000 employees worldwide and achieved 16.2 billion USD in revenue during the 2012 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.

The Monsanto Company (/mɒnˈsæntoʊ/) was an American agrochemical and agricultural biotechnology corporation founded in 1901. In 2018, it was acquired by Bayer as part of its crop science division. It was headquartered in Creve Coeur, Missouri. Monsanto developed Roundup, a glyphosate-based herbicide, in the 1970s, and became a major producer of genetically engineered crops.

Rijk Zwaan Zaadteelt en Zaadhandel BV develops and distributes vegetables and seeds. The company was founded in 1932 and is headquartered in de Lier, the Netherlands.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

National Cancer Center Korea is a South Korean company located in Goyang-si and ultimately controlled by the Government of South Korea. The firm provides clinical and medical research services.

XY LLC develops sex selection technologies for non-human mammals. The company is headquartered in Navasota, TX.

Genea treats natural conception, assisted conception, fertility treatments, iui and ovulation induction, ivf treatment, icsi treatment, freezing, donor and surrogacy, fertility tests, male testing, female testing, genetic testing, and prenatal screening services.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Develops genetically engineered plants

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Xukang Medical Technology (Suzhou) Co., Ltd., established on 2015-04-03, Business scope includes technological development of medical technology and biotechnology,Technology Promotion,technical consulting,Technical Services,technology transfer;genetic analysis,Health Management Consulting;Research and development of biological reagents;Sales of biological reagents for laboratory use;Production and sales of medical supplies and equipment;Sales of laboratory equipment;computer software development;computer,Sales of software and auxiliary equipment;Self-operated and agent import and export business of various commodities and technologies(Excluding commodity technologies that are restricted by the state to be operated by enterprises or prohibited from import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Revivicor is a regenerative medicine company focused on applying leading-edge animal biotechnology platforms to provide a superior quality, high-volume, human-compatible, alternative tissue source for treatment of human degenerative disease.

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.